MD Anderson and Deerfield Management create company to inhibit autophagy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, was formed by MD Anderson Cancer Center, Deerfield Management and two autophagy experts, Eileen White, deputy director and associate director for Basic Science, Rutgers Cancer Institute of New Jersey, and Alec Kimmelman, chairman, Department of Radiation Oncology at NYU Langone Medical Center and a member of the Perlmutter Cancer Center at NYU Langone.

Vescor, advised by its scientific founders White and Kimmelman, will develop small molecule inhibitors of a number of protein targets at critical nodes of the autophagy cascade, perform investigational new drug enabling studies, and move these into clinical development.

MD Anderson’s Institute for Applied Cancer Science, in combination with Deerfield, will provide drug discovery and development expertise, together with translational research focused at advancing autophagy therapeutics into trials in melanoma, lung and pancreatic cancers.

Vescor’s core activities will be performed at IACS, while managerial and operational expertise will be provided by both IACS and Deerfield.

Table of Contents

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login